Drug profile · INN
nimotuzumab
THERALOC
nimotuzumab (THERALOC) is a epidermal growth factor receptor erbb1 inhibitor.
EMA: application withdrawn NMPA: clinical trials
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — nimotuzumab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 15
- Data quality
- 0.83
Quick answer
nimotuzumab (THERALOC) is a epidermal growth factor receptor erbb1 inhibitor.
Key facts
INN nimotuzumab
Brand THERALOC
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nimotuzumab?
nimotuzumab (THERALOC) is a epidermal growth factor receptor erbb1 inhibitor.
What is the brand name for nimotuzumab?
THERALOC is a marketed brand name for nimotuzumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.